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tion, but it likely that this side effect will signiﬁcantly affect the clinical 
use of this very promising class of antineoplastic drugs.
The ubiquitin-proteasome pathway is the major proteolytic system in 
the cytosol and nucleus of all eukariotic cells and a target for anticancer 
chemotherapy. Although it is in no way clear how and where bortezo-
mib (the ﬁrst-in-class proteasome inhibitor) administration can affect 
the peripheral nervous system, at least one-third of the patients under 
treatment have had evidence of clinically-relevant sensory peripheral 
neuropathy. Treatment withdrawal resulted in clinical improvement, 
but the low number of patients studied makes it impossible to draw any 
ﬁrm conclusion about this. 
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Treatment-related pneumonitis continues to be a problem in patients 
receiving thoracic radiotherapy (RT), occurring (≥Grade 3) in 13-16% 
of patients treated with the 3-dimensional RT alone or with concurrent 
chemotherapy. Treatment-related pneumonitis can result in death in 2-
3% of patients. Pneumonitis usually does not affect the delivery of RT, 
being a subacute or late toxicity, but may result in death or signiﬁcant 
disability.
The incidence of treatment-related pneumonitis reported in the RTOG 
experience of four clinical trials of concurrent chemoradiotherapy in 
patients with inoperable NSCLC (Werner-Wasik et al, 2002; Bradley et 
al, 2005) was as follows: Grade 1, 24%; Grade 2, 22%; Grade 3, 16%; 
Grade 4, 2% and Grade 5, 2%. Interestingly, a similar incidence of 
pneumonitis was observed in the RT dose -escalation study of radio-
therapy alone, without chemotherapy (13-16% Grade≥3; Bradley et 
al, 2005). In a recently reported experience from a Phase III SWOG 
(Southwest Oncology Group) 0023 study of concurrent chemoradio-
therapy, docetaxel consolidation and placebo vs. geﬁtinib consolidation 
in 620 NSCLC patients (Gaspar et al, 2005), severe (Grade≥3) pneu-
monitis was observed in 9% of all patients and in 16% of the patient 
subset whose RT records were reviewed in detail. 
Symptomatic pneumonitis classically develops between 1-6 months 
from completion of thoracic RT, although new cases of pneumonitis 
were observed in the RTOG database up to 18 months. It manifests as 
cough, dyspnea and rarely, fever. In patients with chronic lung disease, 
the symptoms of pneumonitis may be difﬁcult to distinguish form the 
underlying lung disease. Treatment-related pneumonitis remains there-
fore a diagnosis of exclusion.
The most current grading system for pneumonitis is that provided by 
the United States NCI (National Cancer Institute) Common Termi-
nology Criteria for Adverse Events v3.0 (CTCAE), where Grade 3 
pneumonitis is deﬁned as “Symptomatic, interfering with Activities 
of Daily Living; oxygen indicated”, and Grade 4 as “Life-threatening; 
ventilatory support indicated”. 
The treatment of established symptomatic treatment-related pneumo-
nitis remains supportive, consisting of prednisone, usually initiated at 
a daily dose of 40-60 mg followed by a very slow taper over several 
weeks. Antibiotics, bronchodilators, oxygen and ventilatory support are 
used as needed.
Several predictive factors are thought to be associated with pneumo-
nitis, including irradiated lung volume, RT dose, RT fraction size and 
frequency, pre-RT lung reserve and interaction with chemotherapy. 
Among the dosimetric tools, the “V
dose
”, or volume of the lung receiv-
ing a certain minimum RT dose (for example, “V
20
”, or volume of the 
lung receiving 20 Gy or more), is a simple and practical tool applicable 
to daily radiation planning. Values of V
20
<25% are rarely (<10%) as-
sociated with radiation pneumonitis (Graham M et al, 1999), although 
such a low V
20
 can be accomplished only for small lung tumors. Most 
cooperative groups (RTOG, SWOG) allow a V
20
 of <35% as a fairly 
safe and yet feasible value for most deﬁnitively treated lung cancers. 
Mean Lung Dose (MLD) is another dosimetric indicator of the risk of 
pneumonitis, which seems to correlate very closely with the V
20
 (Can-
dish et al, 2005). Of note, the validity of the V
20
 is preserved only for 
standard RT fractions. For larger fraction sizes V
20
 values may need to 
be lower (for example, V
20
 becomes V
18
 for a fraction size of 2.5 Gy). 
Hyperfractionated regimens, such as CHART (Continuous Hyperfrac-
tionated Radiation Therapy) may require yet a different V
dose
 as a pre-
dictor of RP. In patients after pneumonectomy, the value of V20 may 
need to be at least halved to predict safe delivery of postoperative RT. 
Despite those limitations, the V
20
 constraint remains a useful guideline 
for patients receiving standard -fractionated RT. Although dosimetric 
parameters are associated with RP risk, they do not have high predic-
tive power (PPV, or Positive Predictive Power of 18-38%; Rodrigues 
et al, 2004). Therefore, biologic models are needed to improve the 
accuracy of prediction.
There are no universally accepted serum markers predicting radiation 
pneumonitis, although TGF-beta (transforming growth factor-beta) has 
been suggested by some investigators to be valuable, particularly when 
combined with a dosimetric factor, such as the V
20
 (Fu 2001). 
So far no measures have been approved as providing effective pre-
vention of pneumonitis. Amifostine administered during concurrent 
chemoradiotherapy in locally advanced NSCLC was reported to lower 
the risk of high-grade pneumonitis in one institutional randomized trial 
(Komaki R et al, 2002), but this observation was not conﬁrmed in the 
large RTOG 98-01 Phase III randomized study (Movsas et al 2005). 
Other potential lung protectors (keratinocyte growth factors, superoxide 
dismutase) will need to be further tested in randomized trials in patients 
with lung cancer to prove their value. 
In summary, RP continues to challenge patients with lung cancer and 
the clinicians taking care of them. More basic and clinical research is 
necessary to accurately predict and treat this complication of therapy of 
thoracic malignancies.
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Pain is not universal in lung cancer, but is common, is present in about 
25% of patients at presentation with an increase to about 50% later. 
Most reviews report that it is often inadequately relieved when severe. 
Pain syndromes found in lung cancer and mesothelioma can be catego-
rised as follows:
1. Sub (retro) - sternal visceral pain 
2. Unilateral visceral pain
3. Chest wall pain (including brachial plexopathy)
4. Post-Thoracotomy 
5. Pain from metastases (especially bone, liver, brain)
